Member Info for Wigwammer

Mr nolupus - in your first post this morning you agreed about the lack of detail in the RNS, and then went on to assert that immupharma are only one of the joint IP holders, while missing out obvious detail and context. You now concede that the CNRS handed over license rights many years ago, since when immupharma have paid to develop the product and consequently own the vast majority of the IP. Any suggestion that this IP is jointly and materially shared with the CNRS is highly misleading. I agree this has been a waste of time and energy, but I do not appear to be alone in believing that you are the main culprit around here. ATB

Indeed nolupus. It only takes people a few minutes research to realise that your first post this morning - stating that Imm are only one of the joint holders - is highly misleading, and lacks requisite detail. The CNRS have already handed over a large part of the rights and immupharma have consequently developed the product to phase 3. From an economic pov, they own the vast majority of the IP. Your suggestion - that the IP is jointly shared - is simply misleading and semantic twaddle. ATB

Immupharma holders can rest assured that the vast majority of whatever economic value sits with those patents belongs to them. And don’t let some duplicitous bore with a weird hang up distract you from this point. ATB

Nolupus said “they are joint holders 50:50 with the CNRS”. Wrong… Nolupus said “they are only one of the joint patent holders”. In any material sense, wrong…. You are being silly, mr nolupus, and anyone with a brain cell can see it. ATB

Frits - well if he has no position currently then I guess just a bit bitter?…. And objectively, mr nolupus, anyone with a brain cell can read your posts this morning and see your knowledge is pretty ropey. But if you want to kid yourself otherwise..

Mr Nolupus,

The patents are not jointly owned in any material sense with the CNRS as you initially suggested. Nor is there ia 50/50 partnership either in terms of patents or licensing royalties with the CNRS, as you later suggest. I find your repeated moralising offensive - given that you have evidently done limited research yourself, and that you repeatedly site negatives while owning the shares. In other words - saying one thing and doing another. Stop the moralising my friend, and people may stop holding up the mirror to you. ATB

I agree supermobileman. It is nothing like 50/50. And to refer to them as “joint partners” without providing detail is highly misleading. From memory - it was about 3% of sales. Mr nolupus has some peculiar weakness where he likes to be seen as “Mr

Moral” - but there is nothing moral about repeatedly misleading people, or owning the shares while encouraging others to do the opposite.

Nolupus,

Certain details lacking from your post too. What percentage of the patent do immupharma own?

It’s even more bizarre that Avion have sustained interest, without any clear strategy to protect the IP. Perhaps they are just not telling us what they know? I hope so, because what we do know is they currently have little protection.

Well of course. Not much point having IP if it isn’t protected. Have they only just considered this?! So where is the detail on how they plan to do it… it’s just a very strange RNS.

Initiating a patent protection strategy?! Well yes, patent protection is a good idea if you’re an IP based company. Almost no detail whatsoever about how they plan to do it. Strange and bizarre communication.

I think nolupus just likes a bit of attention. On the subject of seeing the other side Dallo - what’s the situation with the patents at the minute? Have they got a plan to extend? From memory, US expires 2026, Europe has a bit longer - something like 2032 - both from memory and happy to be corrected.

“Imm invested £2.25 million into Incanthera and they are still on a papier loss on that investment AT this Time…” But so what, nolupus? The thing that matters is whether the value of the incanthera asset was priced in to the valuation of Imm stock. The point that it trades at a paper loss is rather irrelevany if that loss was already priced in to Imm stock… You say you can see the potential here - why not tell us about that?

Indeed. Two sides. You’re learning :)

The obvious point is - if/when we get details of phase 3 and news of a partnership - the shares will no longer be at 2p anymore. They will likely be at some multiple of it. The whole point is to assess the risk/return while in a state of uncertainty, not wait for the uncertainty to be removed and the shares respond. I’m sure some people have lost their shirts in immupharma - but often forgotten - many made excellent returns by buying during the scepticism at 20p, early on during the last phase 3 trial. In fact, by the time the result was announced in 2018, , I had already paid off my original investment by selling shares at a multiple of what I had bought them for - and ran a free position. Happy to be corrected, Ibut I don’t recall the current crop of sceptics among those who ran similar positions..

my largest recovery positions are synthomer, gms and renold. the latter two have really motored over the last 12 months but are well leveraged into recovery. more speculative - speedy hire - rock bottom valuation but quite an opaque near term outlook - could spring up or down short term but hopefully more comfortable mid/long term. highly speculative - carclo and immupharma - proper **** or bust names. buyer beware but potential to multiply many fold if recovery achieved. i also have some asos - hopefully u.k. consumer beyond the worst. happy hunting. imo dyor

Absolutely Yorkshire - I am not suggesting this returns to 180p. But I am suggesting that a similar multiplication off the lows is entirely possible - into the 15-20p range. They just need a small bit of success to start the ball rolling.

The key thing here is this will be a phase 3 - pretty unique for a company of this size. It will take only a very small inflow from an outsourcing deal to bring that point into focus. No more dilution - just a phase 3 in a blockbuster indication. This is what the successful investors recognised prior to the last phase 3 when the shares were 20p or thereabouts , and consequently multiplied above 180p. They need to do very little to kickstart that engine all over again. IMO. DYOR

jeez, just seen jw’s post about me below. “substantive commercial acumen”. pmsl. there is no end to the contrived and meaningless gob****e this person speaks. atb :)

GMHK - well done holding onto your shares and I agree - there are few large liquid shares with equivalent recovery potential to SYNT. In previous posts I’ve estimated that at £7+ within 3 years - which I think is an attractive return and sensible horizon. Hopefully we get there a lot sooner! One of the interesting things from the last results is that over 50% of revenue and an even greater proportion of EBITDA is currently specialty chem - nice premium quality cash flow while we wait for broader recovery… ATB